MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Supernus Pharmaceuticals Inc

Abrir

SetorSaúde

31.9 2.54

Visão Geral

Variação de preço das ações

24h

Atual

Mín

30.81

Máximo

32.27

Indicadores-chave

By Trading Economics

Rendimento

-23M

15M

Vendas

-1.5M

174M

P/E

Médio do Setor

22.947

57.333

EPS

0.548

Margem de lucro

8.801

Funcionários

674

EBITDA

-20M

45M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+23.76% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-410M

1.7B

Abertura anterior

29.36

Fecho anterior

31.9

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Supernus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Alphabet, Intel, AppFolio

24 de abr. de 2025, 23:51 UTC

Conversa de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 de abr. de 2025, 23:37 UTC

Principais Notícias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 de abr. de 2025, 23:36 UTC

Principais Notícias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 de abr. de 2025, 23:13 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 de abr. de 2025, 23:09 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 de abr. de 2025, 22:51 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 de abr. de 2025, 22:48 UTC

Principais Notícias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 de abr. de 2025, 22:47 UTC

Conversa de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 de abr. de 2025, 22:38 UTC

Conversa de Mercado
Ganhos

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 de abr. de 2025, 22:24 UTC

Conversa de Mercado
Ganhos

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 de abr. de 2025, 22:23 UTC

Ganhos

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 de abr. de 2025, 22:09 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 de abr. de 2025, 22:00 UTC

Conversa de Mercado
Ganhos

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 de abr. de 2025, 21:39 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 de abr. de 2025, 21:23 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 de abr. de 2025, 21:04 UTC

Ganhos

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 de abr. de 2025, 21:02 UTC

Ganhos

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparação entre Pares

Variação de preço

Supernus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

23.76% parte superior

Previsão para 12 meses

Média 38.8 USD  23.76%

Máximo 44 USD

Mínimo 36 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

2

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

30.6 / 31.67Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.